Dykstra: The Heat Is On

Maverick's products are used in newly drilled oil and natural gas wells, and for transporting oil and natural gas. Even with Monday's bounce, I still like the outlook for this stock and believe it can at least retest its 200-day moving average at $31.69. The company continually seeks opportunities to enter new markets.

Check out these very impressive numbers: Maverick has a forward price-to-earnings ratio of 6.43, its return on equity (ROE) is an impressive 31.90%, and it has very minimal debt and free cash flow of almost $50 million. They are definitely doing a lot of things right in Chesterfield, Mo.

Double: Pfizer (PFE Quote). Talk about undervalued! This stock does not belong in the $20s. One day we will all wake up and see Pfizer trading back in the $30s.

Pfizer is now the world's largest and most valuable health care company, and it does a whole lot more than just make prescription drugs. Pfizer owns more than 50 different over-the-counter products that you and I use every day, including Visine eye drops and Listerine mouthwash.

I just want to remind everyone that sometimes common sense works: This is one of the greatest American companies of all time. Look up the word "integrity" in the dictionary and you will see a picture of Pfizer's CEO, Hank McKinnell. And by the way, with almost $15 billion in the bank and $9.4 billion of free cash flow, Pfizer is one I'll take on my team anytime.

But that is not the reason I am picking Pfizer today. Again, let me make myself clear: I'm suggesting Pfizer today, because I am here to make you money, plain and simple! Trading at $25.19 as of Monday's close, Pfizer should have no trouble trading back up near its 200-day moving average at $26.70. If you want a "gift," buy 1,000 shares of Pfizer right here.